Effective treatment of hypereosinophilic syndrome with imatinib mesylate

Ziad Salem; Pierre A. Zalloua; Aref Chehal; Nizar Bitar; Miguel Abboud; Adel Kadri; Beatrice Chami; Ali Bazarbachi

doi:10.1038/sj.thj.6200294

Effective treatment of hypereosinophilic syndrome with imatinib mesylate

Ziad Salem, Pierre A. Zalloua, Aref Chehal, Nizar Bitar, Miguel Abboud, Adel Kadri, Beatrice Chami, Ali Bazarbachi

College of Medicine and Health Sciences

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilic syndrome (HES). Six patients with HES were treated daily with 100 mg imatinib mesylate. Five patients had normal karyotype and one showed trisomy 8. RT-PCR was negative for ETV6-PDGFRB and BCR-ABL fusion mRNAs. All patients rapidly achieved complete haematological remission. One patient remained in remission for more than 6 weeks after discontinuing treatment. No significant side effect was noted. Imatinib mesylate should be considered in the first-line therapy of idiopathic HES.

Original language	British English
Pages (from-to)	410-412
Number of pages	3
Journal	Hematology Journal
Volume	4
Issue number	6
DOIs	https://doi.org/10.1038/sj.thj.6200294
State	Published - 2003

Keywords

Eosinophilia
Hypereosinophilic syndrome
Imatinib mesylate
Leukemia

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/sj.thj.6200294

Cite this

@article{39f1a207dc8e4ce7b00634a087fa0e7b,

title = "Effective treatment of hypereosinophilic syndrome with imatinib mesylate",

abstract = "Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilic syndrome (HES). Six patients with HES were treated daily with 100 mg imatinib mesylate. Five patients had normal karyotype and one showed trisomy 8. RT-PCR was negative for ETV6-PDGFRB and BCR-ABL fusion mRNAs. All patients rapidly achieved complete haematological remission. One patient remained in remission for more than 6 weeks after discontinuing treatment. No significant side effect was noted. Imatinib mesylate should be considered in the first-line therapy of idiopathic HES.",

keywords = "Eosinophilia, Hypereosinophilic syndrome, Imatinib mesylate, Leukemia",

author = "Ziad Salem and Zalloua, {Pierre A.} and Aref Chehal and Nizar Bitar and Miguel Abboud and Adel Kadri and Beatrice Chami and Ali Bazarbachi",

year = "2003",

doi = "10.1038/sj.thj.6200294",

language = "British English",

volume = "4",

pages = "410--412",

journal = "Hematology Journal",

issn = "1466-4860",

publisher = "Nature Publishing Group",

number = "6",

}

TY - JOUR

T1 - Effective treatment of hypereosinophilic syndrome with imatinib mesylate

AU - Salem, Ziad

AU - Zalloua, Pierre A.

AU - Chehal, Aref

AU - Bitar, Nizar

AU - Abboud, Miguel

AU - Kadri, Adel

AU - Chami, Beatrice

AU - Bazarbachi, Ali

PY - 2003

Y1 - 2003

N2 - Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilic syndrome (HES). Six patients with HES were treated daily with 100 mg imatinib mesylate. Five patients had normal karyotype and one showed trisomy 8. RT-PCR was negative for ETV6-PDGFRB and BCR-ABL fusion mRNAs. All patients rapidly achieved complete haematological remission. One patient remained in remission for more than 6 weeks after discontinuing treatment. No significant side effect was noted. Imatinib mesylate should be considered in the first-line therapy of idiopathic HES.

AB - Imatinib mesylate treatment is highly effective in chronic myeloid leukaemia and recent data have suggested that imatinib mesylate is also effective in the treatment of idiopathic hypereosinophilic syndrome (HES). Six patients with HES were treated daily with 100 mg imatinib mesylate. Five patients had normal karyotype and one showed trisomy 8. RT-PCR was negative for ETV6-PDGFRB and BCR-ABL fusion mRNAs. All patients rapidly achieved complete haematological remission. One patient remained in remission for more than 6 weeks after discontinuing treatment. No significant side effect was noted. Imatinib mesylate should be considered in the first-line therapy of idiopathic HES.

KW - Eosinophilia

KW - Hypereosinophilic syndrome

KW - Imatinib mesylate

KW - Leukemia

UR - http://www.scopus.com/inward/record.url?scp=0346505232&partnerID=8YFLogxK

U2 - 10.1038/sj.thj.6200294

DO - 10.1038/sj.thj.6200294

M3 - Article

C2 - 14671612

AN - SCOPUS:0346505232

SN - 1466-4860

VL - 4

SP - 410

EP - 412

JO - Hematology Journal

JF - Hematology Journal

IS - 6

ER -

Effective treatment of hypereosinophilic syndrome with imatinib mesylate

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this